Reid Hoffman is leaving the Microsoft boardroom. After a decade of shaping the tech giant’s strategy, the LinkedIn co-founder is stepping down to focus on a new obsession: AI-driven drug discovery.

It is a pivot from corporate governance to the front lines of biotechnology. Hoffman, who joined Microsoft’s board following the $26.2 billion acquisition of LinkedIn in 2016, has spent years at the center of the industry’s most consequential deals. He was present for the initial $1 billion investment in OpenAI and the controversial $650 million deal that brought Inflection AI’s leadership into Microsoft’s orbit. Now, he wants to build.

The Shift to 'Founder Mode'

Hoffman’s departure is not a retirement. It is a re-entry. On a recent episode of his Possible podcast, he told Microsoft CEO Satya Nadella that he is ready to embrace "founder mode" at his latest venture, Manus.

Manus is not a typical software play. It is a drug discovery company that secured over $50 million in seed funding last year. While Hoffman serves as chairman and co-founder, the CEO role belongs to Dr. Siddhartha Mukherjee, the Pulitzer Prize-winning author of The Emperor of All Maladies. The startup is aiming for what Hoffman calls "Move 37" AI—a reference to AlphaGo’s famous, creative move against Lee Sedol. He believes this level of machine intelligence can eventually surpass human creativity in chemistry to combat cancer.

A History of Strategic Influence

Hoffman’s tenure at Microsoft was defined by his ability to bridge the gap between Silicon Valley’s venture culture and the realities of Big Tech. He was a key architect of the company’s pivot toward artificial intelligence. His influence was felt in the boardroom during the rapid integration of OpenAI’s models into Microsoft’s product suite.

However, the lines between his roles have occasionally blurred. He stepped down from the OpenAI board in 2023, citing potential conflicts of interest. His involvement with Inflection AI—which Microsoft effectively absorbed in a move that drew scrutiny from regulators—further complicated his position. By leaving the Microsoft board, Hoffman clears the deck. He is removing the friction of corporate oversight to focus entirely on his own capital and creative output.

What This Means for Manus

Manus is currently in the high-stakes phase of early-stage biotech. With backing from General Catalyst and Hoffman himself, the company is betting that generative AI can solve the "protein folding" problem of drug development.

It is a massive bet. Drug discovery is notoriously slow, expensive, and prone to failure. Hoffman’s transition suggests he believes the technology has reached a tipping point. He isn't just funding the company anymore. He is going to be in the room where the decisions are made.

Key Takeaways

  • Board Exit: Reid Hoffman is stepping down from Microsoft’s board after a decade of influence, including the LinkedIn acquisition and OpenAI partnership.
  • Founder Focus: Hoffman is pivoting to "founder mode" at Manus, an AI-driven drug discovery startup co-founded with Dr. Siddhartha Mukherjee.
  • Strategic Goal: The company aims to leverage "Move 37" AI to outperform human researchers in chemistry and oncology, backed by over $50 million in seed funding.

What happens next is the real test. Hoffman has spent years advising others on how to build at scale. Now, he is putting his own reputation on the line to see if he can apply those same principles to the biology of cancer. The transition is complete. The work begins.